Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer by Milowsky, Matthew I. et al.
Phase 1/2 Multiple Ascending Dose Trial of the Prostate-Specific 
Membrane Antigen (PSMA)-Targeted Antibody Drug Conjugate 
MLN2704 in Metastatic Castration-Resistant Prostate Cancer
Matthew I. Milowsky, MDa,b,1, Matthew D. Galsky, MDa,b,2, Michael J. Morris, MDa,b, Daniel J. 
Crona, PharmD, PhDc, Daniel J. George, MDd, Robert Dreicer, MDe,3, Kin Tse, BSa, Jesika 
Petruck, BSf, Iain J. Webb, MDf, Neil H. Bander, MDg,h, David M. Nanus, MDb, and Howard I. 
Scher, MDa,b
aGenitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer 
Center, New York, NY, USA
bDepartment of Medicine, Weill Cornell Medical College, New York, NY, USA
cDivision of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of 
Pharmacy, University of North Carolina, Chapel Hill, NC, USA
dDepartment of Medicine, Duke University Medical Center, Durham, NC, USA
eTaussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA
fMillennium Pharmaceuticals, Inc., a wholly-owned subsidiary of Takeda Pharmaceuticals 
Company Inc., Cambridge, MA, USA
gDepartment of Urology, Weill Cornell Medical College, New York, NY, USA
hUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, 
NY, USA
Corresponding Author Howard I. Scher, MD, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, 1275 York 
Avenue, New York, NY 10065, Tel: 646-422-4323, Fax: 646-988-0851, scherh@mskcc.org.
1Present address: UNC Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA
2Present address: Division of Hematology and Medical Oncology, Department of Medicine, Icahn School of Medicine at Mount Sinai, 
New York, NY, USA
3Present address: University of Virginia Cancer Center, Charlottesville, VA, USA
Conflict of Interest
Dreicer – Research support: Millenium/Takeda
George –Research support: Millenium/Takeda
Galsky - Research support: Millenium/Takeda 
Crona – None 
Nanus – Research support: Millenium/Takeda 
Webb - Employee of Millennium Pharmaceuticals, a fully owned subsidiary of Takeda Pharmaceuticals International 
Petruck - Employee of Millennium Pharmaceuticals, a fully owned subsidiary of Takeda Pharmaceuticals International
Bander - an inventor on patents that are assigned to Cornell Research Foundation (“CRF”) for anti-PSMA antibody technology. Dr. 
Bander is a paid consultant to and holds equity in BZL Biologics, the company to which the patents were licensed by CRF for further 
research and development.
Scher – Research support: Millenium/Takeda
Milowsky - Research support: Millenium/Takeda 
Disclosures
The study was sponsored by Millennium Pharmaceuticals, Inc., Cambridge, MA, and supported by a grant from the NIH/NCI Cancer 
Center Support Grant (P30-CA008748).
HHS Public Access
Author manuscript
Urol Oncol. Author manuscript; available in PMC 2017 December 01.
Published in final edited form as:
Urol Oncol. 2016 December ; 34(12): 530.e15–530.e21. doi:10.1016/j.urolonc.2016.07.005.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Abstract
Background—This phase 1/2 study evaluated the dose-limiting toxicity and maximum tolerated 
dose of MLN2704, a humanized monoclonal antibody MLN591 targeting prostate-specific 
membrane antigen, linked to the maytansinoid DM1 in patients with progressive metastatic 
castration-resistant prostate cancer.
Patients and methods—Sixty-two patients received MLN2704 at ascending doses on four 
schedules: weekly (60, 84, 118, and 165 mg/m2; 12 patients); every two weeks (120, 168, 236, and 
330 mg/m2; 15 patients); every three weeks (330 and 426 mg/m2; 18 patients); and on days 1 and 
15 of a six-week schedule (6 week cycle, 330 mg/m2; 17 patients). The primary efficacy endpoint 
was a sustained ≥ 50% decline from baseline prostate-specific antigen (PSA) without evidence of 
disease progression. Toxicity, pharmacokinetics, immunogenicity, and antitumor activity were 
assessed.
Results—Neurotoxicity was dose-limiting. 44 patients (71%) exhibited peripheral neuropathy: 
six (10%) had grade 3/4. Neurotoxicity rates remained high despite increasing the dosing interval 
to three- (13 of 14; one grade 3) and six-weeks (16 of 17; three grade 3). MLN2704 
pharmacokinetics were dose-linear. Rapid deconjugation of DM1 from the conjugated antibody 
was seen. Five patients (8%) experienced ≥ 50% decline in PSA; five (8%) had PSA stabilization 
lasting ≥ 90 days. Only two of 35 patients on the three-week and six-week schedules achieved a 
PSA decline of ≥ 50%.
Conclusion—MLN2704 has limited activity in metastatic CRPC. Disulfide linker lability and 
rapid deconjugation lead to neurotoxicity and a narrow therapeutic window.
Keywords
Castration-resistant prostate cancer; DM1; Maytansinoid; MLN2704; Multiple ascending dose; 
PSMA
INTRODUCTION
Prostate-specific membrane antigen (PSMA) is an attractive therapeutic target for castration-
resistant prostate cancer (CRPC). PSMA is a transmembrane protein expressed on virtually 
all tumor cells, is not secreted, and is upregulated after androgen depletion[1]. PSMA is also 
expressed on the vasculature of many solid tumors. MLN591 is a de-immunized anti-
PSMAext monoclonal antibody with a high affinity (1 nM) to the external domain of the 
protein and is rapidly internalized upon binding. MLN2704 is an antibody drug conjugate 
(ADC) composed of MLN591 linked to the potent antimicrotubule chemotherapeutic drug 
maytansinoid-1 (DM1).
A first-in-man trial of MLN2704 studied doses of 18 to 343 mg/m2 administered at four-
week intervals in 23 men with metastatic CRPC and demonstrated safety with repetitive 
dosing and antitumor effects[2]. A maximum tolerated dose was not defined because 
emerging data suggested improved efficacy with more frequent dosing. This phase 1/2 
multiple ascending dose trial in metastatic CRPC was initiated to establish the optimal dose 
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and schedule of the conjugated antibody MLN2704 and to evaluate its pharmacokinetics 
(PK), immunogenicity, and antitumor activity.
PATIENTS AND METHODS
Patient Population
Eligible patients were ≥ 18 yr old with a minimum Karnofsky Performance Status (KPS) of 
60%, a life expectancy > 6 mo, and a diagnosis of progressive metastatic CRPC 
(testosterone < 50 ng/dL). Progression was defined as the presence of at least one of the 
following: 1) progressive soft-tissue disease; 2) new lesions by bone scan; or 3) rising 
prostate-specific antigen (PSA) levels. Eligibility required an absolute neutrophil count 
(ANC) > 1,500/mm4, hematocrit > 27%, and platelet count > 100,000/mm4. Patients were 
excluded if they had received corticosteroids or adrenal hormone inhibitors within 4 weeks 
of entering the trial or if they had received either cytotoxic chemotherapy or radiation 
therapy within 6 weeks. Patients were also excluded if they had received prior monoclonal 
antibodies. Other exclusions included: a serum creatinine > 2.0mg/dL, a serum aspartate 
aminotransferase (AST) or alanine aminotransferase (ALT) > 1.5 times the upper limit of 
normal (ULN), or a bilirubin > 1.25 times the ULN. Patients with peripheral neuropathy of ≥ 
grade 2 (NCI CTCAE version 3.0) were excluded. This study was approved by institutional 
review boards and all patients signed informed consent.
Treatment Plan and Toxicity Assessment
Pretreatment evaluation consisted of a complete history with examination and KPS, 
laboratory studies including PSA and testosterone levels, computed tomography (CT) or 
magnetic resonance imaging (MRI) of the chest, abdomen, and pelvis, and bone scan. 
Patients were assigned sequentially to the currently accruing dose level.
The conjugated antibody was administered as an intravenous infusion in 0.9% saline over 
2.5–3h. Doses ranged from 60 mg/m2 to 462mg/m2. Four dosing schedules were studied: 
once weekly, once every two weeks, once every three weeks, and a six week cycle in which 
doses were administered on days one and 15 followed by a four week off-period. (Figure 1)
Patients exhibiting a response and assigned to the weekly, every second week, and every 
third week schedules were eligible to receive up to six, three, and two additional doses, 
respectively. Responding patients assigned to the six week dosing schedule were eligible to 
receive MLN2704 until found to have progression of disease, up to a maximum of 18 mo.
Three patients were enrolled at the lowest dose in each cohort. If no dose-limiting toxicities 
(DLTs) were observed, dose escalation proceeded to the next higher dose level. DLT was 
defined as the occurrence of one or more NCI CTCAE toxicities and considered possibly 
related to the treatment. Hematologic toxicities included: platelet count < 10,000/mm4; 
platelet transfusion when platelet count < 20,000/mm4; febrile neutropenia; or grade 4 
neutropenia (ANC < 500/mm4) of ≥ 7 d duration. Nonhematologic toxicities included any 
toxicity grade ≥ 3 considered possibly related to the drug. [NCI CTCAE version 3.0]
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DLT cutoffs were: within one week after the fourth dose for patients on the weekly schedule; 
within two weeks after the second dose for patients on the two week schedule; and within 
three weeks after the first dose for patients on the three week schedule. For patients on the 
weekly schedule, a delay in administration of the second, third, or fourth dose was 
considered a DLT if the delay was greater than two days and due to toxicity; for patients on 
the two-week, three-week and six-week schedules, a delay in administration of the second 
dose was considered a DLT if the delay was greater than four days and due to toxicity.
If two DLTs were observed at the first dose level in a cohort, the dose for that cohort was de-
escalated by 40% and three new patients were enrolled at the lower dose level. Assignment 
to the three-week schedule began when at least six patients had received 330 mg/m2 on the 
two-week schedule. No dose escalation/de-escalation was planned for subjects assigned to 
the six-week schedule.
Blood samples were collected at each study visit for the first three doses administered on the 
weekly, two-week, and three-week schedules. Safety was evaluated using laboratory 
assessments, the FACT/GOG NTX 11 questionnaire [3], and monitoring throughout 
treatment until 30 days afterward.
Antitumor activity
Antitumor activity was assessed by changes in PSA levels and/or measurable tumor lesions. 
The primary efficacy endpoint was a sustained ≥ 50% decline from baseline PSA, 
determined by two separate measurements taken no less than four weeks apart, and no 
evidence of disease progression by clinical evaluation and/or radiographic studies. 
Measurable soft-tissue lesions on CT or MRI at screening were reassessed using Response 
Evaluation Criteria in Solid Tumors (RECIST) criteria at 12-week intervals.
Pharmacokinetics and Immunogenicity
Serum concentrations of the conjugated antibody and its individual components were used to 
determine pharmacokinetics (PKs). Concentrations of conjugated antibody (MLN2704), 
deconjugated antibody (MLN591), deconjugated free DM1, and total antibody (sum of 
deconjugated and conjugated antibody) were assessed. The lower limit of DM1 quantitation 
was 0.1 ng/mL. Noncompartmental analysis was used to determine plasma PK parameters, 
including maximum serum concentration levels (Cmax), area under the concentration time 
curve from time zero to infinity (AUC0-∞), half-life (t1/2), and clearance (CL). AUC0-∞ data 
was calculated using a linear-up log-down approach. PK analyses were performed using 
Phoenix WinNonlin version 6.3 (Pharsight Corp, Mountain View, CA). Statistical analyses 
were performed using SAS version 9.2 (SAS Institute Inc., Cary, NC). Samples from 
patients on the weekly and six-week dosing schedules were not included in the PK analyses 
due to insufficient data related to assay sensitivity and/or sampling time issues.
Immunogenicity was assessed by measuring serial serum levels of anti-MLN591 and anti-
MLN2704 antibodies.
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RESULTS
Patient Characteristics
Sixty-two patients with metastatic CRPC were enrolled at academic medical centers (Table 
1). 27 (44%) had measurable disease and 35 (56%) received prior chemotherapy.
Dosing Schedules
The conjugated antibody dosing schedules and number of patients treated at each dose level 
are shown in Figure 1 and Supplemental Table 1.
Adverse Events
Adverse events observed in ≥ 15% of patients are presented in Table 2. Peripheral 
neuropathy occurred in 44 cases (71%), and was grade 3/4 in six (10%). Other common 
toxicities included nausea (61%), fatigue (60%), anorexia (39%), and diarrhea (39%). 
Fifteen patients (38%) discontinued treatment secondary to an adverse event (Supplemental 
Table 1).
A protocol amendment increased the dosing interval and introduced the three-week schedule 
for patients receiving doses ≥ 330 mg/m2. 14 patients received 330mg/m2 every three weeks. 
In this cohort, 12 patients developed peripheral neuropathy: one developed grade 3 
neuropathy while 11 developed less than grade 3 neuropathy. (Table 2)
Five of 17 (29%) patients on the six-week schedule (330 mg/m2) discontinued treatment due 
to at least one adverse event. (Supplemental Table 1) Grades 2 and 3 peripheral neuropathy 
developed in five and three patients, respectively. One patient in this cohort developed grade 
3 AST/ALT elevation. (Table 2) In multivariate analysis, prior neuropathy, prior taxane 
therapy, and diabetes mellitus were not predictors for worsening neuropathy.
Pharmacokinetics and Immunogenicity
Dose-linear PKs were observed in the conjugated antibody across the range of doses 
analyzed in this study (Table 3). Conjugated antibody exposure, determined by Cmax and 
AUC0-∞, was dose-proportional at levels ranging from 120 to 462 mg/m2. Significant linear 
relationships between both Cmax and AUC0-∞ and conjugated antibody doses were 
observed, where dose escalations corresponded with proportional increases in Cmax (r2 = 
0.95; p < 0.0001) and AUC0-∞ (r2 = 0.92; p <0.0001). At 330 mg/m2, significant differences 
in exposure between the two-week and three-week dose schedules were likely due to modest 
accumulation of the conjugated antibody. Mean Cmax and AUC0-∞inf levels of the 
conjugated antibody tended to increase during the second and third cycles across dose levels 
ranging from 120 to 462 mg/m2.
A significant inverse relationship between conjugated antibody (MLN2704) clearance and 
dose was detected across a range of dose levels (120–462 mg/m2): the higher the dose, the 
slower the clearance (r2 = 0.31; p = 0.0014), similar to the first-in-man study of 
MLN2704[2]. The relationship was no longer present when the 120 mg/m2 dose level was 
excluded (r2 = 0.17; p = 0.13). MLN2704 clearance was approximately 2 times and 2.5 
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times more rapid than the apparent clearance of the free antibody and the total antibody, 
respectively (Figure 2). The majority of conjugated antibody was cleared within seven days 
after each of the first three cycles although conjugated antibody levels remained detectable 
for up to 30 days.
A dose schedule–exposure relationship was also observed. Significant differences between 
mean Cmax (p = 0.0002) and AUC0-∞ (p = 0.01) were evident when the 330 mg/m2 
conjugated antibody dose was administered every two weeks relative to every three weeks. 
However, a dose schedule–clearance relationship was not observed between patients on 
these two schedules (p = 0.1).
Free DM1 levels were measurable in serum samples from all patients treated with 120–462 
mg/m2 during cycles 1–3 (Supplemental Table 2). After a dose of 330 mg/m2, peak plasma 
levels of free DM1 were >200 ng/mL throughout all three cycles for patients on the two- and 
three-week schedules. Similar to findings for the conjugated antibody, pretreatment serum 
samples from subjects receiving 330 mg/m2 revealed a detectable greater accumulation of 
free DM1 among patients on the two-week schedule when compared to those on the three-
week schedule. Also similar to the conjugated antibody findings, the apparent clearance of 
free DM1 was more rapid than the apparent clearance of both free antibody and total 
antibody (Figure 2).
No antibodies were detected to MLN2704, MLN591, or free DM1 at any time point.
Antitumor Effects
PSA response—Figure 3 shows a waterfall plot of the maximal PSA decline by dose 
level. Overall PSA response rate is summarized in Supplemental Table 3. Five patients (8%) 
experienced a ≥ 50% PSA decline for a median duration of 86 days (range, 56–520 days) 
and five patients (8%) experienced PSA stabilization (PSA ≤ 25% above baseline for ≥ 90 
days). Activity was seen in both chemotherapy-naïve patients and those with prior 
chemotherapy. One instance of ≥ 50% PSA decline was observed at a 168mg/m2 dose level 
and the remaining four were seen at a 330 mg/m2 dose level: of these, two patients received 
330mg/m2 on the two-week dosing schedule and two received 330mg/m2 on the six-week 
schedule. Two patients with PSA stabilization received 330 mg/m2 on the two-week 
schedule. These findings supported evaluating a less frequent dosing schedule for 330 
mg/m2 and above to further determine activity and decrease potential neurotoxicity. 
However, no PSA responses were seen on the three-week dosing schedule and only two of 
17 patients (12%) treated on the six-week schedule had PSA responses.
Measurable disease—No tumor regressions were seen in measurable soft-tissue lesions, 
although 35% remained stable.
DISCUSSION
The first-in-man study of MLN2704 showed dose-dependent antitumor effects without 
significant peripheral neuropathy, but further dose escalations performed in the current study 
along with repetitive dosing proved to be limited by DLTs[2]. The toxicities occurred most 
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commonly after the second or third dose. Overall efficacy was also limited, as only five 
patients (8%) experienced a ≥ 50% PSA decline and five had PSA stabilization lasting ≥90 
days; four of those showing a PSA response received 330 mg/m2 every two weeks. Less 
frequent dosing did not maintain efficacy or reduce neurotoxicity.
The etiology of the peripheral neuropathy associated with MLN2704 is likely due to 
deconjugation in plasma of the small-molecule antimicrotubule, DM1, from the large-
molecule antibody, MLN591. Similar PKs, deconjugation rates, and toxicity patterns 
(including peripheral neuropathy) were observed in a phase I trial of an immunoconjugate 
targeting MUC1, cantuzumab mertansine [4]. In this study, both free DM1 and free antibody 
were detectable in a time-dependent fashion shortly after catabolism of MLN2704 and 
plasma clearance. Free DM1 was detectable for up to 30 days after the third treatment cycle, 
providing evidence that free DM1 is not immediately metabolized and eliminated after rapid 
deconjugation from MLN591.
The PKs of MLN2704 are complex because it has been formulated with a small molecule 
(DM1) attached to a large molecule (MLN591 antibody) at lysine residues by a 
thiopentanoate linker. Intracellular reduction of a disulfide bond within the thiopentanoate 
linker allows DM1 to be released at the site of action within prostate cancer cells expressing 
PSMA. ADC disulfide linkers have been shown to be significantly more labile than other 
types of linkers: this results in reduction of the disulfide bond in the plasma rather than 
within cancer cells as intended[5]. Phase 1 and phase 2 clinical trials involving the ADC 
trastuzumab emtansine (T-DM1) have demonstrated that immunoconjugates formulated with 
a less labile thioether linker are sufficiently potent and even at high doses do not have the 
same toxicity profile as MLN2704[6,7]. An average of three to five molecules of DM1 are 
attached to every antibody molecule of both the MLN591 antibody and trastuzumab: the 
differences in pharmacodynamic profiles between the two agents are likely due to 
formulation differences at the linker[6,8].
MLN2704 linker instability is exemplified by comparing peak plasma levels from this phase 
1/2 trial to those from the phase 1 T-DM1 trial. In the T-DM1 trial, peak plasma levels of 
free DM1 were < 10 ng/mL for all dose levels[6]. However, we observed > 20-fold higher 
levels of free DM1 at the 330 mg/m2 dose in patients on the two-week and three-week 
schedules. A > 20-fold increase of circulating DM1 in the periphery could plausibly explain 
both the lower than expected PSA response and the high incidence of peripheral neuropathy.
Radiolabeled anti-PSMA based therapy is an alternative strategy to a toxin conjugate 
approach. Since October 2000, five studies have evaluated Lutetium-177 (177Lu) 
radiolabeled anti-PSMA monoclonal antibody J591 (177Lu-J591) in patients with metastatic 
CRPC[9]. In a phase II study in patients with progressive metastatic CRPC at a dose of 65–
70 mCi/m2, significant PSA declines were seen in 60% of patients. Myelosuppression was 
the dose limiting toxicity. Dose fractionation alone or in combination with docetaxel 
chemotherapy has also resulted in significant PSA declines. 177Lu imaging studies have 
demonstrated accurate targeting of metastatic sites in > 90% of patients. Alternative PSMA 
targeting with radiolabeled small molecules involving radioligand therapy rather than an 
antibody based approach have been investigated with interesting results. The small molecule 
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approach circumvents issues with antibody based approaches including the slow diffusion of 
antibodies into solid lesions and the prolonged circulation time of antibodies associated with 
an increased risk for toxicity. The DOTA-conjugated ligand PSMA-617 with high binding 
affinity and long tumor retention has been evaluated in metastatic CRPC with promising 
results[10,11]. In a retrospective experience with 74 consecutive analyzable patients with 
metastatic CRPC selected for PSMA expression by 68Ga-PSMA-11 PET/CT who received a 
single dose of 177Lu-PSMA-617, a PSA decline was seen in 47 (63%) with 23 (31%) having 
a > 50% decline with minimal toxicity. Another experience with 177Lu-PSMA radioligand 
therapy in 56 patients with metastatic CRPC revealed PSA responses in 45 of 56 (80.4%) 
patients, radiologic responses and excellent tolerability. Hematologic toxicity was minimal 
and significantly less than what is seen with 177Lu-J591 where the mean absorbed dose 
of 177Lu-J591 delivered to the red marrow is 20-fold higher than what was seen with 177Lu-
PSMA radioligand therapy[12]. Radioimmunotherapy for metastatic CRPC has 
demonstrated promising results with several ongoing trials in patients with advanced 
prostate cancer.
Overall, the results provide further validation of PSMA as a therapeutic target for 
immunoconjugates with more favorable PK and pharmacodynamic profiles. Here, linker 
instability, increased dose intensity relative to the previous phase 1 clinical trial, and the 
detection of free DM1 with a long-terminal elimination led to an unfavorable safety profile 
that precluded further study.
CONCLUSIONS
While there is proof-of-concept evidence supporting MLN2704 as a potentially effective 
agent for patients with CRPC, it possesses an extremely narrow therapeutic window. 
Thiopentoate linker lability leads to rapid catabolism and deconjugation of DM1 from the 
conjugated antibody. Increased DM1 levels are the likely etiology for the toxicity leading to 
the narrow therapeutic window. This study provides a rationale for developing anti-PSMA 
ADCs for CRPC treatment utilizing novel linker strategies to avert toxicity.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Highlights
1. MLN2704, an antibody drug conjugate targeting PSMA was evaluated in 
metastatic CRPC.
2. MLN2704 at multiple ascending doses had limited activity in metastatic 
CRPC.
3. Neurotoxicity with peripheral neuropathy was dose-limiting.
4. Disulfide linker lability and rapid deconjugation led to a narrow therapeutic 
window.
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Fig. 1. 
Multiple ascending doses and schedules
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Fig. 2. 
Mean levels of MLN2704, total MLN591 antibody, free MLN 591 antibody, and free DM1 
after three cycles at the maximum tolerated dose of 330mg/m2 administered every two (top) 
and every three (bottom) weeks. Error bars indicate the standard deviation.
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Fig. 3. 
Maximal PSA decline in all patients
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Table 1
Patient and Disease Characteristics
Characteristics n = 62
Age, median (range), y 69 (52–84)
KPS (n = 57), median, range* 90 (70–100)
Measurable disease, no. of patients (%) 27 (44)
Prior therapies, no. of patients (%)
 Surgery 33 (53)
 Radiation 37 (60)
 Any chemotherapy 35 (56)
 Taxane-based chemotherapy 33 (53)
 Hormone therapy 62 (100)
Baseline laboratory parameters
 Albumin (g/L), median (range) 41 (31–48)
 Alkaline phosphatase (units/L), median (range) 121 (38–836)
 Hemoglobin (g/dL), median (range) 131 (111–144)
 LDH (units/L), median (range) 201.5 (108–700)
 PSA (ng/mL), median (range) 56.8 (3.7–5241)
KPS = Karnofsky Performance Status; LDH = lactate dehydrogenase; PSA = prostate-specific antigen.
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